NCT03710421View on ClinicalTrials.gov

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 23, 2019

Primary Completion Date

March 24, 2026

Study Completion Date

March 24, 2026

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
PROCEDURE

CS1-CAR T Therapy

Undergo CS1-CAR T therapy

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

PROCEDURE

Leukapheresis

Undergo leukapheresis

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER